← Search & browse all drugs
NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Calcitonin gene-related peptide (CGRP) antagonists
galcanezumab
N02CD02
Forms & Strengths
- 100mg/mL solution for injection in a prefilled syringe
- 100mg/mL solution for injection in a prefilled pen
Adult Dosing
- 240mg as initial loading dose via two consecutive subcutaneous injections of 120mg each
- Maintenance dose: 120mg via subcutaneous injection once monthly
Pediatric Dosing
- Safety and efficacy not established in patients under 18 years of age
Indications
- Prevention of episodic migraine
- Treatment of episodic cluster headache
Mechanism of Action
- Humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP)
- Inhibits CGRP receptor binding and CGRP-induced responses
Adverse Reactions
- Injection site reactions
- Allergic reactions
- Constipation
- CPRP antibody development
Drug Interactions
- No specific interactions identified to date
Curated Content: Needs Vetting Before Put to Clinical Use